Metacam 2mg/ml Solution for Injection for Cats

Χώρα: Ηνωμένο Βασίλειο

Γλώσσα: Αγγλικά

Πηγή: VMD (Veterinary Medicines Directorate)

Δραστική ουσία:

Meloxicam

Διαθέσιμο από:

Boehringer Ingelheim Vetmedica Gmbh

Φαρμακολογική κατηγορία (ATC):

QM01AC06

INN (Διεθνής Όνομα):

Meloxicam

Φαρμακοτεχνική μορφή:

Solution for injection

Τρόπος διάθεσης:

POM-V - Prescription Only Medicine – Veterinarian

Θεραπευτική ομάδα:

Cats

Θεραπευτική περιοχή:

Anti Inflammatory NSAID

Καθεστώς αδειοδότησης:

Authorized

Ημερομηνία της άδειας:

2010-07-02

Αρχείο Π.Χ.Π.

EMA Version
September 2021- AN: 01220/2021
Page 1 of 6
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Metacam 2 mg/ml solution for injection for cats
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
One ml contains:
ACTIVE SUBSTANCE:
Meloxicam
2 mg
EXCIPIENTS:
Ethanol
150 mg
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for
injection.
Clear yellow
solution.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cats
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Alleviation of mild to moderate post-operative pain and inflammation
following
surgical procedures in cats, e.g. orthopaedic and soft tissue surgery.
4.3
CONTRAINDICATIONS
Do not use in pregnant or lactating animals.
Do not use in cats suffering from gastrointestinal disorders such as
irritation and
haemorrhage, impaired hepatic, cardiac or renal function and
haemorrhagic disorders.
Do not use in cases of hypersensitivity to the active substance or to
any
of the excipients. Do not use in cats less than 6 weeks of age nor in
cats
of less than 2 kg.
EMA Version
September 2021- AN: 01220/2021
Page 2 of 6
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
If adverse reactions occur, treatment should be discontinued and the
advice of a
veterinarian should be sought.
Avoid use in any dehydrated, hypovolaemic or hypotensive cat, as there
is a
potential risk of renal toxicity.
During anaesthesia, monitoring and fluid therapy should be considered
as
standard practice. In case additional pain relief is required,
multimodal pain
therapy should be considered.
Special precautions to be taken by the person administering the
veterinary medicinal
product to animals Accidental self-injection may give rise to pain.
People with known
hypersensitivity to non-steroidal anti- inflammatory drugs (NSAIDs)
should avoid
contact with the veterinary medicinal product.
In case of accidental self-injection, seek medical advice immediately
and show the
packa